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We previously described a synthetic peptide of 
myelin  proteolipid  protein (PLP), peptide 139-151, 
which  induces  experimental  allergic  encephalomye- 
litis in  SJL/J (H-2") mice. We have  now  identified  an 
additional  determinant, PLP residues  178-1 91, that 
is also a potent  encephalitogen  in this strain. When 
PLP peptide 178-191 was compared with peptide 
139-  15 1 on  an  equimolar basis, the  day  of onset of 
disease induced by PLP 178-191 was earlier, but 
the  incidence,  severity,  and  histologic  features were
indistinguishable. Lymph node cells from animals 
immunized  with  the  whole PLP molecule  responded 
to both PLP 178-191 and 139-151, suggesting  im- 
munologic codominance of the two epitopes. PLP 
178-1 91 elicited stronger proliferative responses 
and this may relate to the  earlier  onset of disease 
induced with this peptide. Two CD4+, peptide-spe- 
cific, I-A"-restricted T cell lines, selected by stimu- 
lation of  lymph  node cells with  either PLP 178-191 
or 139- 151, were each encephalitogenic in naive 
syngeneic  mice. The presence of  multiple  encephal- 
itogenic codominant PLP epitopes within a single 
mouse  strain  emphasizes  the  complexity of the im- 
mune  response to PLP and its potential as a target 
Ag in  autoimmune  demyelinating diseases. 
EAE3 is a T  cell-mediated  autoimmune  disease  that is 
widely used as a model for MS. I t  has  long been  known 
that EAE can  be induced in  laboratory  animals by im- 
munization  with  spinal cord homogenate, CNS myelin,  or 
the major myelin protein constituents (1, 2). The  ence- 
phalitogenic  activity of  MBP and MBP peptides has  been 
studied  extensively  and  has  been  the  basis  for  therapeu- 
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tic  strategies  for EAE and MS. However, MBP alone  does 
not account for all of the encephalitogenic activity of 
myelin. More recently, PLP, the  most  abundant  protein 
constituent of CNS myelin, has been  accepted as a major 
encephalitogen (3-7). PLP is a hydrophobic, polytopic 
integral  membrane  protein  with  physical  and  chemical 
properties  that  have  made  it  difficult  to  study.  Synthetic 
peptides  based on the PLP sequence  have now  begun  to 
provide information on its immunologic  properties. 
Encephalitogenic PLP epitopes  have  been  identified  in 
strains of mice representing  several H-2 haplotypes. PLP 
139-  15 1 (HCLGKWLGHPDKF) is  encephalitogenic in S J L  
(H-2") mice (6), PLP 103-1 16 (YKTTICGKGLSATV) in 
SWR (H-2q) mice (7). PLP 215-232 (GKVCGSNLLSICK- 
TAEF) in C3H (H-2") mice (8). and PLP 43-64 (EKLIE- 
TYFSKNYQDYEYLINVI) in  PL/J (H-2") mice (9). Thus  far, 
only a single PLP determinant  has been  identified in  any 
one  mouse  strain,  thereby  limiting  the  scope of the im- 
munologic studies  that  can  be  carried  out.  The  identifi- 
cation of additional encephalitogenic epitopes within a 
single strain  and  the  characterization of the T cell re- 
sponses  to  such  determinants would permit  more com- 
plete analysis of the  immune  response  to  the whole PLP 
molecule. This  information would provide insight  for un- 
derstanding  analogous  responses  in  humans. 
A previous  study  in S J L  mice  indirectly  suggested an  
encephalitogenic  epitope(s) in addition  to PLP 139-151, 
in  that  some encephalitogenic PLP-specific T cell clones 
cross-reacted  with DM-20 (5). DM-20 is  an  alternatively 
spliced  form of PLP in  which  residues 1 16-150  are de- 
leted (10). In our  study, we report  the  identification  and 
characterization of a second  encephalitogenic  epitope of 
PLP in S J L  mice. PLP 178-191 (NTWTTCQSIAFPSK) has 
been  found  to  induce  severe EAE in  this  strain.  Further- 
more,  mice  immunized  with the whole PLP molecule  re- 
spond  strongly  to  both  peptides  139- 15  1 and  178-  19  1, 
suggesting a codominant recognition of these determi- 
nants. Some of the  properties of encephalitogenic  T cell 
lines  specific  for  the  two  epitopes  are  also  described. 
MATERIALS AND METHODS 
Mice.  Female  SJL/J (H-2") mice  were  purchased  from  The  Jackson 
Laboratory,  Bar  Harbor, ME. They  were  age  matched for each  exper- 
iment and were immunized at 10 to 14 wk of age. Various H-2" 
congenic  mice  (A.TL,  BlO.HTT, and  A.TH) were  obtained from Dr. 
David Sachs  (National  Institutes of Health,  Bethesda, MD). 
PLP  and PLP peptides. PLP was prepared by concentrating a 
washed  total lipid extract of bovine  white  matter (1 1) and  partially 
removing lipids by acetone extraction. The protein was then dis- 
solved  in  chloroform-methanol-acetic  acid (2: 1 :0.03 by  volume)  and 
the  remaining  lipids  were  removed  by  two  passages  through a Seph- 
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adex LH-60 column  equilibrated and eluted with  the  same solvent 
mixture  (1  2). Conversion of  PLP to  the  aqueous  form  was  carried  out 
by evaporation of the organic  solvent in a stream of nitrogen and 
was dialyzed a t  4°C against  three  changes of double distilled deion- 
gradual  replacement  with water  (1  3). Finally, the  aqueous solution 
ized water to remove acid. 
PLP (14, 15). Peptides 103-116,  139-151,  and  178-191 were syn- 
PLP peptides  were prepared according to  the  sequence of murine 
thesized  in the laboratory of Dr. R. Laursen  (Department of Chem- 
istry, Boston University, Boston, MA) on a Milligen model 9050 
synthesizer (Millipore Corp., Bedford. MA), using FMOC chemistry. 
were used as  the solid support. Peptides 170-  189  and 180- 199 were 
Milligen PAL resins, which  produce  peptides with C-terminal  amides. 
a generous gift from Dr. D.  A. Hafler (Brigham and Womens Hospital, 
Boston, MA). The  sequences of these peptides are  shown in Table 1. 
100 Kg of whole PLP or PLP peptide(s) and  200 pg of Mycobacteria 
Active  induction of EAE. Mice were injected S.C. in the  flank with 
tuberculosis H37Ra (Difco Laboratories,  Detroit, MI] in  an emulsion 
consisting of equal  volumes of water  and CFA (Difco). Peptide 178- 
191  was dissolved in  0.02 M acetic  acid,  because it was  not soluble 
in water.  Each mouse was  also injected i.v. on days 0 and 3 with 4.5 
X lo9 Bordetella pertussts bacilli (pertussis vaccine, lot no. 264, 
Massachusetts Public Health Biologics Laboratories, Boston, MA), 
unless otherwise stated. Control mice received identical treatment 
as test  animals, except that PLP or PLP peptides  were  not  added. 
Clinical  and  histologic  evaluation. Mice were assessed clinically 
as previously described (4) according to the following criteria: 0, no 
disease;  1. decreased  tail tone or slightly  clumsy gait; 2. tail atony 
and/or moderately clumsy  gait and/or poor righting  ability; 3, limb 
weakness;  4, limb paralysis;  and 5, moribund state. Animals  were 
killed within  10  days of the initial appearance of clinical signs of 
disease. Mice that showed  no  clinical signs were killed 25  to  28  days 
after  immunization.  Brains  and  spinal cords  were removed and fixed 
in 10% phosphate-buffered formalin, and paraffin embedded sec- 
tions were stained  with luxol fast blue-hematoxylin and eosin  for 
light microscopy. Histologic disease  was  quantitated by counting  the 
inflammatory foci in  meninges  and  parenchyma  as previously de- 
scribed (16). 
Preparation of LNC and T cell  lines. Pooled LNC were prepared 
from inguinal  lymph  nodes  from  two to  three mice injected 8 days 
earlier  with a single S.C. injection of 100 pg whole PLP or PLP peptide 
in CFA. Control animals were injected with a n  emulsion of  CFA and 
water (or 0.02 M acetic acid). 
Thereafter, LNC were  used  for  proliferation assays, or were stim- 
ulated  with PLP peptide 139- 15 1 or 178- 19 1 to produce Ag-specific 
T cell lines.  T cell lines were maintained in RPMI containing T cell 
growth promoter (American Bio-Technologies Inc..  Cambridge, MA] 
and  stimulated two to  three  times at  approximately 10- to 15-day 
intervals with 20 pglml PLP peptide, using mitomycin C-treated 
syngeneic  splenocytes as APC. 
mAb. The following cell lines producing mAb (with  their espective 
tion, Rockville, MD:  TIB 105 (CD8). 14.4.4,s ([-Ek), 10.2.16 (]-AS), and 
specificities) were obtained  from the American Type Culture Collec- 
H0.13.4 (Thy-1.21. mAb 145.2C11 (CD3), GK1.5 (CD4). and H57.597 
(TCR-&) were  obtained  from  Drs. Jeffrey Bluestone (University of 
Chicago, Chicago, IL). Frank Fitch  (University of Chicago], and Ralph 
Kubo (National Jewish  Center for Immunology and Respiratory Med- 
icine, Denver, CO), respectively. Antibodies were used as  culture 
supernatants  or,  for anti-I-A antibody, as ascites. 
Prolijerattve  assay.  The  in vitro  proliferative responses of LNC 
and T cell lines were assayed  in triplicate in 96-well microtiter  plates. 
LNC were  used at a concentration of 3 X lo5 cells/well.  T cell lines 
were used at  5 x lo4 cells/well with 5 X lo5 mitomycin C-treated 
splenocytes/well as APC. Cells were incubated  for  72 h at  37°C in 
5% C02 in the presence or  absence of Ag. One pCi of [3H]TdR was 
added during  the  final  18  to  20 h of culture.  The  plates were har- 
vested using a PHD cell harvester (Cambridge Technology. Cam- 
bridge, MA) and counted using standard liquid scintillation tech- 
niques in  a  Beckman  scintillation counter model LS5000  (Beckman 
Instruments Inc.. Fullerton, CA). In some  experiments,  various mAb 
were added to block the Ag-specific proliferative response of T cell 
TABLE I 
Sequences of PLP peptides  used" 
Peptide Sequence M.W. 
PLP 103-1 16 
PLP 139-151 
YKTTICGKGLSATV 
HSLGKWLGHPDKF 
1439 
1519 
PLP 170-189 AVPVYIYFNTWTTCQSIAFP 2966 
PLP 178-191 
PLP 180- 199 WTTCQSIAFPSKTSASIGSL 
NTWTTCQSIAFPSK 
2090 
1573 
for the native C at position 140 in peptide 139-151 (6). 
a Sequences shown are based on murine PLP (1 4. 15). S was substituted 
lines. These blocking assays were set up following the methods 
described previously (17). The data are expressed as stimulation 
indices (SI] that were  determined by the  formula: 
mean cpm of Ag-containing  triplicate  wells 
mean cpm of control  triplicate wells 
S I  = 
All SD were ~ 1 5 %  of the  mean. 
Flow cytornetric analysis. Samples containing at  least 1 X lo6 
cells  were incubated on ice for 30 min  with  20 to 50 pl of hybridoma 
culture  supernatant  and  washed two or three  times with PBS con- 
taining  0.1 % BSA and  0.1 % NaN3. These  samples were then  incu- 
bated for 30 min with 25 pl of the appropriate FITC-conjugated 
second antibody reagent. Second step reagents included a 1/50 
dilution of FITC-conjugated rabbit  anti-hamster Ig, goat anti-rat Ig, 
or goat anti-mouse Ig (Cooper Biomedicals, Organon  Tecknica. Mal- 
vern. PA]. After the  final  incubation,  samples were washed  twice, 
fixed in 1% paraformaldehyde. and analyzed on a FACS  SCAN 
(Coulter Corp.. Hialeah, FL). 
Passive  transfer of EAE. Cell lines were cultured  in the  presence 
of 20 pg/ml of the specific peptide. After 3 days, dead cells were 
removed on a Ficoll gradient. Live cells were washed twice and 2 x 
lo6 cells  were injected i.v. into naive  recipient mice. 
RESULTS 
Induction of disease  with  peptide 178-1 91. In the 
course of attempts  to produce  antibodies  against  defined 
regions of PLP, we immunized pairs of S J L  mice with 
either PLP peptide  170-  189  or  180-  199  (100 wg peptide/ 
mouse in CFA). These mice did not receive pertussis 
vaccine.  Nevertheless,  both mice  receiving PLP 170- 189 
and  one  mouse receiving PLP 180- 199 developed severe 
EAE 13  to  15  days  postimmunization  with  clinical  dis- 
ease  scores of 3 to  4. 
Inasmuch as the two  peptides  overlap and  both  cause 
disease,  it  seemed likely that  the overlapping  region  cor- 
responded to a n  encephalitogenic epitope. To confirm 
this  observation,  eight S J L  mice were immunized with 
PLP peptide  178- 19 1  by the  standard protocol described 
in Materials and Methods. Four control mice received 
the same treatment, except that peptide was not in- 
cluded. All mice receiving injections of PLP 178-191 
developed EAE 11  -13  (1  2.4 f 0.7) days postinjection. 
Clinical signs  were  severe,  with a mean  clinical  score of 
4.8. None of the control  mice developed clinical  signs of 
EAE. 
Histologically, meningeal  inflammatory  infiltrates 
were  present over the  entire  neuraxis of mice  immunized 
with PLP 178-  19 1  (Fig. la). Perivascular,  predominantly 
perivenous, inflammation was present in optic nerves 
and in cerebral periventricular, cerebellar, brain stem, 
and spinal cord white matter. Infiltrates consisted of 
mixtures of mononuclear  inflammatory  cells  and  neutro- 
phils  with  more  neutrophils  in  the  parenchyma  than  in 
the  meninges. No inflammation  was  present  in  the  cho- 
roid plexus,  spinal  nerves,  or  other  cranial  nerve  roots. 
Small foci of perivascular demyelination were present 
adjacent  to  dorsal root entry  zones  in  the  spinal  cords. 
None of the control  mice  had histologic disease. 
Comparison of disease induction by equimolar 
amounts of two  encephalitogenic  peptides. To  compare 
the encephalitogenic activity of the two S J L  determi- 
nants, PLP 139- 15 1 and 178- 19 1, groups of mice  were 
immunized  with  equimolar  amounts of each peptide and 
then  evaluated  for  the  development of EAE. Twelve of 12  
animals immunized  with PLP 178-  191  and  10/12 mice 
immunized with PLP 139-151 developed clinical signs 
(Table 11). At peptide  concentrations  ranging  from  10  to 
50 nmol,  disease  was  severe  in  both  groups. Mice immu- 
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Ffgure 1 .  Histologic features of EAE in PLP 178-191 immunized SJL 
mice. a. Perivascular mononuclear cell infiltrates with associated mild 
demyelination (arrowheads) in the cerebellar white matter. b. Infiltration 
of neutrophils and mononuclear cells in the optic nerves. c. Mononuclear 
cell infiltrate in the  spinal cord. Sections are from CNS tissue of mice that 
had been sensitized with 25 to 64 nmol (39-100 ~ g )  PLP peptide 178- 
blue-hematoxylin and  eosin, 125x. 
191. 12 to 15 days previously and had clinical scores of 5. Lux01 fast 
nized with PLP 178- 19 1  consistently developed EAE ear- 
lier than those immunized with  139- 15 l (1  2.8 f 0.8 vs 
19.4 f 3.9 days; p < 0.001). but the maximal clinical 
scores  and histologic features of the  disease were essen- 
tially the  same in the two  groups. Histologically, typical 
EAE lesions,  with  associated  demyelination  in  some 
cases, were observed in all mice immunized with the 
various  doses of PLP 178-191 (Fig. 1, b and c ) .  and in all 
except one immunized with PLP 139- 15 1. Control mice, 
which received either no peptide or an irrelevant PLP 
peptide, showed no  clinical or histologic disease. 
Proliferative responses of LNC from  mice immunized 
with whole PLP or peptide 178-191. LNC from mice 
injected with PLP 178-191 responded strongly to the 
immunizing  peptide  in proliferative assays (Fig. 2a).  The 
stimulation  indices  ranged from 6 to 17, depending on 
peptide concentration.  The  response of these LNC to PLP 
139- 15 1 was  no more than two to three  times  the back- 
ground  count and  there  was  no  response to the control 
peptide 103-1  16. The LNC from mice immunized with 
whole PLP responded to both of the encephalitogenic 
peptides,  but the  response  to peptide 178-191 was con- 
sistently greater than that to peptide 139-151. when 
tested at  concentrations of 25 or 50 pg/ml (Fig. 2b). LNC 
from control mice did not  respond to any of the peptides. 
Two possible reasons for the  enhanced  response to PLP 
178-191 by LNC from mice immunized with whole PLP 
are  that PLP 178-191 is more immunogenic,  or that  the 
presence of DM-20 in the PLP preparation  increases the 
amount of this peptide in the immunizing  material. To 
test the  latter, mice were immunized with mixtures of 
the two peptides. LNC from mice immunized with equi- 
molar amounts of the two peptides responded more 
strongly to PLP 178-191 than to 139-151 (Fig. 3a). and 
the responses  were  comparable to those observed with 
whole PLP-immunized mice (Fig. 2b). Next, the relative 
immunogenicity of the two peptides was tested by im- 
munizing mice with mixtures of the peptides  in  which 
the molar amount of  PLP 139-1 5 1 was kept constant  but 
the  amount of PLP 178-191 was decreased. The prolif- 
erative responses of the LNC to peptides 139-151 and 
178- 19 1 were approximately  equal  when the mice were 
immunized  with 2.5  times more PLP 139-1 51 (Fig. 3b). 
Even when 10  times more PLP 139-1 51  was used, sig- 
nificant proliferative responses to PLP 178-191 were 
observed (data not shown). 
Production  and  characterization of T cell Ilnes. T cell 
lines were derived from the LNC of S J L  mice after im- 
munization with PLP peptides  139- 15 1 or 178- 19 1. Line 
E- 13.S.  specific  for PLP 139- 15  1, responded to PLP pep- 
tide 139- 15  1,  but not  to  178- 19 1. Similarly,  line P- 17.S. 
specific  for PLP 178-191,  responded to this peptide, but 
not to 139- 15 1 (Fig. 4). Flow cytometric analysis showed 
that both lines were Thy-1.2+, CD3'. CD4'. CD8-. and 
TCR-aP+ (data  not  shown). 
To further  characterize  the T cell lines, the effect of 
adding mAb specific  for CD4, CD8, I-A", and LEk on  the 
stimulation of lines E-13.S and P-17.S by their respective 
Ag was investigated. Anti-CD4  mAb blocked the prolif- 
erative response of both lines (94% inhibition of the 
response of E-13.S to PLP 139-151, and  77% inhibition 
of the  response of P-17.S  to PLP 178-191).  whereas anti- 
CD8 and  anti-I-Ek  antibodies did not block (5-20%  inhi- 
bition). Anti-I-A"  mAb partially blocked the proliferative 
responses of both lines  (approximately 50% inhibition for 
each  line). It was  not  clear from this  result  whether  the 
anti-LA" mAb was inefficient under the experimental 
conditions, or whether  the  lines were  restricted by ele- 
ments  other  than I-A". Therefore,  to  determine the MHC 
restriction of the T cell lines,  splenocytes from congenic 
strains of mice that differ from S J L  at  various H-2  loci 
were used as potential APC in proliferative assays. APC 
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TABLE II 
Comparison of EAE induction  with  equimolaramounts of PLPpeptides 139-151 and 178-191 
Clinical  EAE 
Peptidea 
Histologic  EAE 
Incidence  Day of onsetb Score'  Inciden e No. focid 
178-191 
10 nmol 
25 nmol 
50 nmol 
139-151 
25 nmol 
10 nmol 
50 nmol 
Controls 
103-116 
50 nmol 
414 13.0 (12-14) 3.8 (1-5) 
414 
414 111 + 7 7  
49 + 36 
414 12.8  (12- 3) 4.3 (3-5) 414 185 & 97 
12.5 (11-14) 4.0 (3-5) 414 
314 16.6 (14-18)  3.0  (2-5) 314 
314 
414 
414 
414 
139 & 20 
102 & 45 
88 + 41 
20.7 (16-26) 
20.5  (16-26) 
3.7 (2-5) 
4.0 (4) 
0 012 0 
no peptide 014 0 014 0 
"Mice were immunized with 10, 25 or 50 nmol of PLP 139-151 or PLP 178-191. and 50 nmol of PLP 103-116 as  
described  in  Materials  and Methods. 
Mean maximum  clinical  score and  range of animals  with  disease. 
Values are  mean  day  after  inoculation  and ranges  for  each  group. 
Mean + SD of number of inflammatory foci in  meninges  and  parenchyma of mice with histologic EAE or control mice. 
0 1 0  20 30 40 50 0 1 0  2 0  30 4 0  50 
Peptide  concentration (uglrnl) 
Figure2. Proliferative response of  LNC from mice immunized with 
100 pg of PLP peptide 178-191 (a)  or 100 pg of whole PLP (b). LNC were 
obtained from two or three mice 8 days  after  immunization  and  were 
tested  for  their  ability  to  proliferate  to  peptides. LNC (3 x 105/well)  were 
incubated  for 72 h  with  various  concentrations of PLP 139-151 (8). PLP 
178-191 ( + I ,  or PLP 103-1 16 ( 0 ) .  One pCi of [3H]TdR was  added  during 
the  last 16 to 18 h of incubation.  Data  are  presented  as  mean  stimulation 
and b. 1749. 
indices from a  representative  experiment. Background cprn were: a. 1212 
- 
0 1 0  2 0  30 4 0   5 0  0 1 0  2 0  30 4 0  50 
Peptide  concentration (uglml) 
equimolar  amounts (50 nmol) of  PLP peptides 139-151 + 178-191 ( a )  or 
Figure 3. Proliferative responses of LNC from mice immunized  with 
50 nmol of  PLP 139-151 + 20 nmol of  PLP 178-191 (b). LNC were 
prepared and tested as described in the legend to Figure 2. Data are 
presented as mean  stimulation  indices  from  a  representative  experiment. 
Background cpm  were: a. 660 and b, 2894. 
from SJL,  A.TH and B1O.HTT mice,  all of which  express 
I-A", could present Ag to both T cell lines and induce 
specific proliferative responses (Table 111). In contrast, 
splenocytes from A.TL mice, which express I-Ak, were 
unable  to  present  antigen to either cell line.  Therefore, 
the T cell lines recognize their  respective Ag in  the  context 
of I-A". The lower stimulation  indices  for B1O.HTT mice 
Line E-13.S 
300 -I 
0 
1 0  20 
r Line P-17.S 
80 -I 
-I- 
I 
Peptide concentration (uglml) 
~. 0 1 0  2 0  
Ag. T cells (5 x 1 04/well) and syngeneic APC (5 x 105/well) were incubated 
Figure 4. Proliferative  responses of T cell lines E-13.S and P-17.S to 
for 72 h  with  various  concentrations of PLP 139-151 (8). PLP 178-191 
(+) or PLP 103-1 16 (0 ) .  One pCi  of [3H]TdR was added during  the  last 16 
to 18 h of incubation.  Data  are  presented  as  mean  stimulation  indices 
and 3413 for P-17,s. 
from a representative experiment. Background cprn = 1131 for E-13.S 
TABLE Ill 
Proliferatiue  responses of T cell lines  using APC from mice  with 
dGerent MHC haplotypes 
APC Donor Mice' ti::','.' Peptideb sJL A.TH BIO.HTT A.TL 
IK'ABDsl (KSASDd] IKBABEkDk) (KBAkEkDd] 
139-151 184.1d  182.9  14.3 0.8 
1.4 0.9 
103-116 1.4 1.2 1.1  0.9 
1 .o 1.1 E-13.S 178-191 
139-151 1 .o 1.6 1 .o 
P-17,s 178-191 279.6 457.5  17.2 
0.8 
0.8 
103-1 16 0.9 1.2 0.8 0.9 
described  in the text. 
" T  cell lines E-13.S and P-17.S were selected and grown in vitro as  
*Peptides  were  added to proliferation  assays at  a  concentration of 5 
strains of mice indicated. 
APC were  in  the  form of mitomycin C-treated  splenocytes from the 
2,000 when S J L  and A.TH splenocytes were used as  APC. and 40,000 to 
Values  represent  stimulation  indices. Background cpm were 500 to 
60,000 when B1O.HTT or A.TL were used. 
rg[ml. 
reflect  higher  background cprn (40,000-60,000) for  cul- 
tures  containing B l  O.HTT splenocytes as APC, compared 
to background cpm of 500 to 2000 with SJL  or A.TH 
splenocytes. Despite this, significant proliferative  re- 
sponses were still observed with antigen. High back- 
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ground cpm also occurred when A.TL splenocytes were 
used as APC. This  effect  was probably due  to alloreactiv- 
ity of  TCR Vpl7 bearing  T cells to I-E molecules expressed 
on APC from the B1O.HTT and A.TL mice (18). 
The  ability of lines  E-13.S and P-17.S  to  induce EAE 
after  transfer  in vivo was  tested. Both lines were found 
to be encephalitogenic  when injected i.v. into  naive SJL 
mice (Table IV). Mice that received line P- 17s developed 
disease more rapidly than did those that received line E- 
1 3 5  However, the  latter group  had more severe  disease. 
Histologically, the adoptively transferred disease was 
identical to that induced by active  sensitization  with PLP 
peptides 139- 15 1 and 1  78- 19 1. 
DISCUSSION 
This is the  first report of multiple encephalitogenic PLP 
epitopes within a single strain of mice. However, more 
than one PLP epitope for S J L  mice was indirectly sug- 
gested by two previous studies. Van der Veen et  al.  (19) 
derived several PLP-specific T cell clones from S J L  mice. 
Only some of the clones were specific for residues  139- 
15  1, thereby implying the existence of an additional  ep- 
itope. Satoh  et  al. (5) found that some encephalitogenic  T 
cell lines from PLP-immunized mice responded to DM- 
20,  as well as  to PLP, implying that  an additional  ence- 
phalitogenic epitope is present outside the 1  16- 150 re- 
gion. We have  shown that PLP peptide 178-191 is ence- 
phalitogenic in S J L  mice and  that disease can be  pas- 
sively transferred by a T cell line responding to that 
peptide. 
Recently, Endoh et al. [8) reported that sensitization 
with bovine DM-20 did not  induce EAE in SJL mice. In 
view of our  results, an  encephalitogenic  response might 
have been expected.  The apparent discrepancy could be 
related to sequence  differences between bovine and 
mouse PLP. Although the sequence of  PLP is highly con- 
served, there  are several  differences between the bovine 
and mouse molecules. In the mouse,  residue 188 is phen- 
ylalanine,  whereas it is alanine in the bovine sequence 
(20).  The peptide that we found to be encephalitogenic 
was  synthesized  according  to the mouse sequence,  and it 
is possible that  the phenylalanine  residue is critical  for 
disease  induction.  Endoh et al. (8) also reported that a 
mixture of bovine PLP peptides  (1 81 -21  1 + 212-276) 
failed to  induce EAE. This could be due to the differences 
between the bovine and mouse sequences or the  absence 
of a  critical  residue(s) at  the N-terminus.  Furthermore, it 
is possible that  the mixture of the two large peptides may 
contain  suppressor epitopes that prevent EAE. We have 
previously found that whereas peptide 139- 15 1  induces 
severe  disease in S J L  mice, the larger peptide 137-154 
is not as effective (6). More recent  studies  show that  the 
presence of additional residues flanking PLP 139-151 
TABLE IV 
Adootive  transfer  of EAE 
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results  in  a tolerogenic response  (21)  and/or  induction of 
Ts cells (V. K. Kuchroo, unpublished  observations). 
Our results  indicate little difference  in the incidence, 
severity, or histologic features of EAE induced by PLP 
peptides 139- 15 1 and 178- 19 1. However, PLP 178- 19 1 
induced disease more rapidly, and  this may relate to its 
greater immunogenicity. We considered that  the stronger 
proliferative response to PLP 178- 191 in whole PLP- 
immunized mice might be attributable  to  the  presence of
DM-20 in the PLP preparation. Peptide 178-191 is pres- 
ent in both PLP and DM-20, whereas peptide 139-151 is 
only in PLP. DM-20 is not separated from PLP by the 
methods used in  our  study and, as a  consequence.  there 
is more 178- 19 1 than 139- 15 1 in the immunizing prep- 
aration. Nevertheless, when equimolar amounts of the 
two synthetic  peptides were injected together, PLP 178- 
191  still induced a  stronger  response and  the responses 
were comparable only when  there  was  at least 2.5 times 
more peptide 139-151.  This  difference could be due to 
more efficient  binding to the I-A" molecule or to  recruit- 
ment of a  larger  T cell repertoire. Alternatively. the rela- 
tive insolubility of PLP 178-191  under nonacidic condi- 
tions may lead to its aggregation, thereby  increasing  the 
efficiency of presentation by  APC to Ag-specific T cells. 
The  codominant recognition of  PLP 139- 15 1 and 178- 
19 1 described herein is in direct contrast to  observations 
on MBP epitopes. EAE studies involving MBP have  shown 
multiple immunogenic and encephalitogenic epitopes 
within single mouse strains (22-24). However, after im- 
munization  with the whole MBP molecule, the response 
is predominantly directed against  a single epitope (24- 
26).  Similarly,  when  (PL/J X SJL)FI mice are immunized 
with whole MBP, a  T cell response is observed only to the 
PL/J determinant (MBP peptide Acl-9) but not to the 
S J L  determinant (MBP 89-101).  further  emphasizing  the 
dominance of a single MBP determinant in inducing  a  T 
cell response (27). To some extent, the immunodomi- 
nance of a single epitope may account for the relatively 
limited or restricted TCR usage in the response to MBP 
(28-31) and  the  success of TCR and peptide-based ther- 
apies in preventing MBP-induced EAE (30-34). 
We have  recently described that, in contrast to MBP, 
TCR usage by T cells recognizing PLP 139-1 51 in S J L  
mice is diverse (1 7).  The xistence of multiple codominant 
determinants  within  this  strain may further  increase  the 
diversity of the T cell response against the whole PLP 
molecule. It is also possible that a  comparable complexity 
of T cell responses to PLP exists in humans. Indeed, T 
cells from some MS patients  have been shown  to respond 
to  several PLP peptides (35). suggesting that  the response 
to PLP in humans may also be directed against multiple 
determinants rather than a single dominant epitope. 
This  raises  the question as to whether  therapy directed 
against  one of the PLP epitopes would be sufficient to 
protect against the encephalitogenic effects of other 
determinants. 
~ 
Clinical  EAE  Hlstologic EAE" 
T Cell Lfne 
Incidence Day of onsetb  ScoreC No. focid 
E- 13.S 
P-17.S 
3/3  13.3 112-14) 4.5 50.0 f 16.3 
5/5 7.6 (6-91 2.5 32.4 i- 8.8 
a Histologic disease  was  observed in all mice. 
Mean maximum  clinical  score. 
Values  are  mean day after  transfer  and  ranges for each group. 
Mean f SE of number of inflammatory foci in  meninges  and  paren- 
chyma. 
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